Success Metrics

Clinical Success Rate
83.9%

Based on 26 completed trials

Completion Rate
84%(26/31)
Active Trials
0(0%)
Results Posted
31%(8 trials)
Terminated
5(14%)

Phase Distribution

Ph not_applicable
2
5%
Ph phase_2
4
11%
Ph phase_1
16
43%

Phase Distribution

16

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
16(72.7%)
Phase 2Efficacy & side effects
4(18.2%)
N/ANon-phased studies
2(9.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.3%

26 of 32 finished

Non-Completion Rate

18.8%

6 ended early

Currently Active

0

trials recruiting

Total Trials

37

all time

Status Distribution
Completed(26)
Terminated(6)
Other(5)

Detailed Status

Completed26
Terminated5
unknown5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
0
Success Rate
83.9%
Most Advanced
Phase 2

Trials by Phase

Phase 116 (72.7%)
Phase 24 (18.2%)
N/A2 (9.1%)

Trials by Status

withdrawn13%
completed2670%
terminated514%
unknown514%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT00646230Phase 1

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Completed
NCT00540982Phase 1

Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction

Completed
NCT00667121

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed
NCT05506358Not Applicable

Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada

Completed
NCT01206465Phase 1

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Completed
NCT00959244

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

Completed
NCT00569543

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Completed
NCT00900224

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Unknown
NCT00900055

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Completed
NCT00645060Phase 1

Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

Completed
NCT00691652Phase 1

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Terminated
NCT00900367

Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women

Unknown
NCT00909831Phase 1

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

Completed
NCT00897208

Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer

Completed
NCT00513461Phase 2

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

Completed
NCT00770471Phase 1

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
NCT00738452Phase 1

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

Completed
NCT00873366

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

Terminated
NCT01383447Phase 1

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Terminated
NCT00550563Not Applicable

DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements

Completed

Drug Details

Intervention Type
OTHER
Total Trials
37